Literature DB >> 8789353

The elusive family of imidazoline binding sites.

A Parini1, C G Moudanos, N Pizzinat, S M Lanier.   

Abstract

Various imidazoline and guanidinium derivatives elicit diverse cellular responses in peripheral and nervous tissues that are often difficult to attribute to known receptor signalling systems. Biochemical, functional and clinical evidence suggests that some activities of these compounds may be related to their action on defined imidazoline binding sites, which have been recently characterized. Unexpectedly, and of particular significance, recent data indicate that two members of the family of imidazoline binding sites are identical to the A and B isoforms of monoamine oxidase. In this article, Angelo Parini and colleagues summarize the evidence for the characterization and location of imidazoline binding sites, and speculate on the clinical implications of compounds acting on these sites.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8789353     DOI: 10.1016/0165-6147(96)81564-1

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  26 in total

Review 1.  Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?

Authors:  Andrew Holt
Journal:  J Psychiatry Neurosci       Date:  2003-11       Impact factor: 6.186

2.  Change in the Binding of [11C]BU99008 to Imidazoline I2 Receptor Using Brain PET in Zucker Rats.

Authors:  Kazunori Kawamura; Tomoteru Yamasaki; Yiding Zhang; Hidekatsu Wakizaka; Akiko Hatori; Lin Xie; Masayuki Fujinaga; Ming-Rong Zhang
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

3.  Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia.

Authors:  Yonghua Zhang; Harold K Kimelberg
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

4.  Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress.

Authors:  P Sikirić; B Mazul; S Seiwerth; Z Grabarević; R Rucman; M Petek; V Jagić; B Turković; I Rotkvić; S Mise; I Zoricić; L Jurina; P Konjevoda; M Hanzevacki; M Gjurasin; J Separović; D Ljubanović; B Artuković; M Bratulić; M Tisljar; P Miklić; J Sumajstorcić
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

5.  Targeting imidazoline site on monoamine oxidase B through molecular docking simulations.

Authors:  Fernanda Pretto Moraes; Walter Filgueira de Azevedo
Journal:  J Mol Model       Date:  2012-03-17       Impact factor: 1.810

6.  Imidazoleacetic acid-ribotide in vestibulo-sympathetic pathway neurons.

Authors:  Gay R Holstein; Victor L Friedrich; Giorgio P Martinelli
Journal:  Exp Brain Res       Date:  2016-07-13       Impact factor: 1.972

7.  Distribution and cellular localization of imidazoleacetic acid-ribotide, an endogenous ligand at imidazol(in)e and adrenergic receptors, in rat brain.

Authors:  Victor L Friedrich; Giorgio P Martinelli; George D Prell; Gay R Holstein
Journal:  J Chem Neuroanat       Date:  2007-01-08       Impact factor: 3.052

8.  Inhibition of 5-HT3 receptor function by imidazolines in mouse neuroblastoma cells: potential involvement of sigma 2 binding sites.

Authors:  G J Molderings; K Schmidt; H Bönisch; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

9.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

10.  Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site.

Authors:  Atsuko Kimura; Robin J Tyacke; James J Robinson; Stephen M Husbands; Michael C W Minchin; David J Nutt; Alan L Hudson
Journal:  Brain Res       Date:  2009-05-03       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.